You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultra-Sensitive Molecular Diagnostic for Borrelia Species

    SBC: ATOM SCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The aim of the proposed research is to develop an enabling technology that will allow development of a molecular diagnostic for identification and discrimination among closely related bacterial species that cause signif icant disease at low microorganism numbers. The technology will be advanced through the development of a diagnostic system for detection of spe ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Public Rights-of-Way Assessment Instrumentation to Determine Accessibility

    SBC: BENEFICIAL DESIGNS INC            Topic: N/A

    Cities must perform detailed assessments of sidewalks and streets, including curb ramps, pedestrian signals, crosswalks, street furniture, and other components to determine compliance with the Public Rights-of-Way Accessibility Guidelines. However, current assessment methods are inadequate or unreasonable due to time and resources required. The objectives of this project are to: 1) develop elect ...

    SBIR Phase I 2008 Department of Transportation
  3. "CULTURING AMPHIBIANS FOR BIOMEDICAL RESEARCH"

    SBC: Central Valley Biological Inc            Topic: N/A

    N/A

    SBIR Phase I 1984 Department of Health and Human Services
  4. PictureRx: An Intervention to Reduce Latino Health Disparities

    SBC: SAI INTERACTIVE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Major health disparities in chronic disease control and outcomes exist among Latinos, the fastest growing segment of the U.S. population. If these disparities continue, demographic trends will magnify their adverse health, societal, and economic impact. Chronic disease control often requires successful management of multiple prescription medications, yet many p ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Method for Analyzing Non-poly(A) RNA Transcripts

    SBC: GENHUNTER CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Much efforts in gene expression analysis in the past have been focused mainly on the messenger RNAs (mRNAs), thanks to the availability of Differential Display (DD), SAGE and DNA microarray technologies, which all targ et the poly(A) tails present in most eukaryotic mRNAs. The recent discovery of a large microRNA population begged the question of whether there ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. THE PAST DECADE HAS SEEN A GREAT IMPETUS IN THE SEARCH FOR TUMOR MARKERS FOR THE DETECTION AND MANAGEMENT OF CANCER.

    SBC: Jcl Clinical Research Corp            Topic: N/A

    THE PAST DECADE HAS SEEN A GREAT IMPETUS IN THE SEARCH FOR TUMOR MARKERS FOR THE DETECTION AND MANAGEMENT OF CANCER. THIS SEARCH HAS LED TO THE DISCOVERY OF SEVERAL OTHER CARCINOFETAL PROTEINS SUCH AS VARIENTS OF CEA AND ALPHA FETOPROTEINS. THE TUMOR MARKER, TENNESSEE ANTIGEN, APPEARS TO DIFFER SIGNIFICANTLY FROM CEA IN MOLECULAR WEIGHT, MOBILITY IN IMMUNOELECTROPHORESIS, CARBOHYDRATE RESIDUE CONT ...

    SBIR Phase I 1984 Department of Health and Human Services
  7. A NEW TUMOR-ASSOCIATED ANTIGEN, CALLED TENNESSEE ANTIGEN (TAG), HAS BEEN ISOLATED FROM 95% OF 154 PRIMARY HUMAN GASTRAINTESTINAL TUMORS.

    SBC: Jcl Clinical Research Corp            Topic: N/A

    A NEW TUMOR-ASSOCIATED ANTIGEN, CALLED TENNESSEE ANTIGEN (TAG), HAS BEEN ISOLATED FROM 95% OF 154 PRIMARY HUMAN GASTRAINTESTINAL TUMORS. IN 208 PATIENTS WITH COLORECTAL CARCINOMA, 81% SHOWED ELEVATED LEVELS OF TAG IN THEIR SERUM. IN THIS PROPOSAL, TAG WILL BE ISOLATED FROM EXTRACT OF ADENOCARCINOMA OF HUMAN GASTROINTESTINAL TRACT. MONOCLONAL ANTIBODIES (MOAB) AGAINST TAG WILL BE PRODUCED. SPLEEN C ...

    SBIR Phase I 1984 Department of Health and Human Services
  8. Topical Skin Treatment to Facilitate Wound Healing in the Aged Population

    SBC: MOLECULAR DESIGN INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. This agent also induces epidermal thickening. However, un like RA, MDI-301 is non-irritating when applied topically. In a recent study we showed that MDI-301 was effective in promoting the healing of s ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. A biodegradable ophthalmic drug delivery device

    SBC: Notus Laboratories, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Our long-term research goal is to develop an ophthalmic, nanofiber-based, biodegradable device that will provide extended release of therapeutic agents to the posterior segment of the eye via transscleral and intravitr eal approaches. This platform device will address the major technical problem in the treatment of posterior eye diseases (diabetic retinopathy, ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an LPA receptor modulator Rx100 as a radioprotectant

    SBC: Rxbio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Bone marrow and gastrointestinal mucosa are highly sensitive to radiation exposure. Radiation-induced damage to bone marrow and the gastrointestinal tract could be lethal in events such as nuclear accidents or radiation terrorism, depending on radiation doses, exposure rate and quality. No truly satisfactory radioprotective drugs are yet available. The phospho ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government